SMTL ID : 3vzv.1 (1 other biounit)

Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x VZV: 1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-6-methyl-3-(propan-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-N,N-dimethyl-L-prolinamide(Non-covalent)

VZV.1: 11 residues within 4Å: Chain A: L.32, L.35, G.36, I.39, M.40, Y.45, Q.50, V.71, H.74, I.77, Y.78 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:I.39, A:I.39, A:Y.45, A:V.71

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Miyazaki, M. et al., Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Bioorg.Med.Chem.Lett. (2013)

Release Date

2013-02-06

Peptides

E3 ubiquitin-protein ligase Mdm2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

E3 ubiquitin-protein ligase Mdm2

Related Entries With Identical Sequence